Cover Image

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study

This 2-stage Phase III study (NCT04142242) of a recently licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) assessed the safety and immunogenicity of a booster dose in older adults (≥59 years) primed with either MenACYW-TT or a quadrivalent meningococcal polysaccharide...

Full description

Saved in:

Bibliographic Details
Main Authors:	Corwin A. Robertson (Author), Jeffry Jacqmein (Author), Alexandre Selmani (Author), Katherine Galarza (Author), Philipp Oster (Author)
Format:	Book
Published:	Taylor & Francis Group, 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age
by: Corwin A. Robertson, et al.
Published: (2024)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion
by: Silvia Ricci, et al.
Published: (2023)

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study
by: Germán Áñez, et al.
Published: (2020)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
by: Timo Vesikari, et al.
Published: (2020)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study
by: Judith Kirstein, et al.
Published: (2020)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
by: Markus Knuf, et al.
Published: (2022)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
by: Gary S. Marshall, et al.
Published: (2022)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
by: Samba O. Sow, et al.
Published: (2023)

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study
by: Franco M. Piazza, et al.
Published: (2022)

Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older
by: David P. Greenberg, et al.
Published: (2017)

The impact of meningococcal conjugate vaccine (MenACWY-TT) on meningococcal carriage in Hajj Pilgrims returning to Turkey
by: Hasan Tezer, et al.
Published: (2020)

Current safety issues with quadrivalent meningococcal conjugate vaccines
by: Tanya R. Myers, et al.
Published: (2018)

Systematic literature review on the safety and immunogenicity of rotavirus vaccines when co-administered with meningococcal vaccines
by: Priya Pereira, et al.
Published: (2020)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
by: Véronique Abitbol, et al.
Published: (2023)

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine
by: Pavitra Keshavan, et al.
Published: (2018)

Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12-23 months in China
by: Jialei Hu, et al.
Published: (2019)

Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
by: Sara Viksmoen Watle, et al.
Published: (2021)

The effect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males
by: Rebecca F. Wu, et al.
Published: (2017)

Safety and immunogenicity of a novel quadrivalent subunit influenza vaccine in animal models
by: Huayue Ye, et al.
Published: (2020)

No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial
by: Abdi Naficy, et al.
Published: (2024)

Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review
by: Tracy a Becerra-Culqui, et al.
Published: (2021)

Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines
by: Lidia Serra, et al.
Published: (2021)

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents
by: Timo Vesikari, et al.
Published: (2021)

Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study
by: Nan-Chang Chiu, et al.
Published: (2018)

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age
by: Timo Vesikari, et al.
Published: (2020)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
by: Suzanne M. Garland, et al.
Published: (2022)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years
by: Ivette Maldonado, et al.
Published: (2022)

Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis
by: Yu Liang, et al.
Published: (2021)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
by: Cecilia Montalban, et al.
Published: (2018)

Safety and immunogenicity of meningococcal (Groups A and C) polysaccharide vaccine in children 2 to 6 y of age in China: a randomized, active-controlled, non-inferiority study
by: Feng-Cai Zhu, et al.
Published: (2021)

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
by: Beatriz P. Quiambao, et al.
Published: (2017)

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
by: Timo Vesikari, et al.
Published: (2020)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
by: Sharad Agarkhedkar, et al.
Published: (2019)

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study
by: Ingrid Herta Rotstein Grein, et al.
Published: (2020)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
by: Daniela Amicizia, et al.
Published: (2023)

Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine
by: Beatriz Quiambao, et al.
Published: (2020)

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea
by: Won Suk Choi, et al.
Published: (2018)

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial
by: Ahmet Omma, et al.
Published: (2022)

Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study
by: Asmik Asatryan, et al.
Published: (2021)

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in India
by: Nijalingappa K. Kalappanavar, et al.
Published: (2022)